Login to Your Account

Amgen's Kepivance Approved For Mucositis In Blood Cancers

By Randall Osborne

Friday, December 17, 2004
As expected, Amgen Inc. won FDA approval of Kepivance (palifermin), its fast-track keratinocyte growth factor for mucositis in chemotherapy patients with blood cancers who get bone marrow transplants. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription